{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T15:42:28Z","timestamp":1764603748665,"version":"3.37.3"},"reference-count":96,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,8,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The introduction of targeted immunotherapies specifically, brentuximab vedotin (BV) and programmed death-1 (PD-1)\u2013blocking antibodies (nivolumab and pembrolizumab), has reshaped the therapeutic landscape of classical Hodgkin lymphoma (cHL) in the past decade. Targeting specific biologic features of cHL, these novel agents have expanded treatment options for patients with multiply R\/R cHL and have increasingly been studied at earlier points in a patient\u2019s disease course. With the plethora of studies evaluating BV and PD-1 blockade as part of cHL therapy, often in nonrandomized, controlled studies, more questions than answers have arisen about how to optimally integrate these drugs into clinical practice. In this article, we use a case-based format to offer practical guidance on how we incorporate BV and anti-PD-1 antibodies into the management of cHL and review the data supporting those recommendations.<\/jats:p>","DOI":"10.1182\/blood.2020007900","type":"journal-article","created":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T03:32:24Z","timestamp":1619148744000},"page":"520-530","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["How I incorporate novel agents into the treatment of classical Hodgkin lymphoma"],"prefix":"10.1182","volume":"138","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8216-3457","authenticated-orcid":false,"given":"Narendranath","family":"Epperla","sequence":"first","affiliation":[{"name":"Division of Hematology, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9665-7415","authenticated-orcid":false,"given":"Alex F.","family":"Herrera","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2021,4,22]]},"reference":[{"issue":"7","key":"2021081915275264200_B1","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMra1003733","article-title":"Early-stage Hodgkin\u2019s lymphoma","volume":"363","author":"Armitage","year":"2010","journal-title":"N Engl J Med."},{"issue":"27","key":"2021081915275264200_B2","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/JCO.2008.19.8820","article-title":"Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin\u2019s lymphoma: 10 years of follow-up of the GHSG HD9 study","volume":"27","author":"Engert","year":"2009","journal-title":"J Clin Oncol."},{"issue":"17","key":"2021081915275264200_B3","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2015.63.1119","article-title":"US intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest Oncology Group S0816","volume":"34","author":"Press","year":"2016","journal-title":"J Clin Oncol."},{"issue":"25","key":"2021081915275264200_B4","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med."},{"issue":"17","key":"2021081915275264200_B5","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med."},{"issue":"8852","key":"2021081915275264200_B6","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin\u2019s disease: results of a BNLI randomised trial","volume":"341","author":"Linch","year":"1993","journal-title":"Lancet."},{"issue":"9323","key":"2021081915275264200_B7","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet."},{"issue":"36","key":"2021081915275264200_B8","doi-asserted-by":"crossref","first-page":"5980","DOI":"10.1200\/JCO.2007.15.5887","article-title":"Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse\/refractory Hodgkin\u2019s lymphoma: results of the prospective multicenter H96 trial by the GELA\/SFGM study group","volume":"26","author":"Morschhauser","year":"2008","journal-title":"J Clin Oncol."},{"issue":"9980","key":"2021081915275264200_B9","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet."},{"issue":"25","key":"2021081915275264200_B10","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1182\/blood-2018-07-861641","article-title":"Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse","volume":"132","author":"Moskowitz","year":"2018","journal-title":"Blood."},{"issue":"1","key":"2021081915275264200_B11","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/phar.1170","article-title":"Brentuximab vedotin: a CD30-directed antibody-cytotoxic drug conjugate","volume":"33","author":"Newland","year":"2013","journal-title":"Pharmacotherapy."},{"issue":"17","key":"2021081915275264200_B12","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood."},{"issue":"18","key":"2021081915275264200_B13","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol."},{"issue":"12","key":"2021081915275264200_B14","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","article-title":"Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma","volume":"128","author":"Chen","year":"2016","journal-title":"Blood."},{"issue":"9","key":"2021081915275264200_B15","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol."},{"issue":"14","key":"2021081915275264200_B16","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 Trial [published correction appears in J Clin Oncol. 2018;36(26):2748]","volume":"36","author":"Armand","year":"2018","journal-title":"J Clin Oncol."},{"issue":"19","key":"2021081915275264200_B17","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol."},{"issue":"14","key":"2021081915275264200_B18","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1182\/blood.2019000324","article-title":"Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087","volume":"134","author":"Chen","year":"2019","journal-title":"Blood."},{"issue":"12","key":"2021081915275264200_B19","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann Oncol."},{"issue":"10","key":"2021081915275264200_B20","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1634\/theoncologist.2016-0055","article-title":"Management of adverse events following treatment with anti-programmed death-1 agents","volume":"21","author":"Weber","year":"2016","journal-title":"Oncologist."},{"key":"2021081915275264200_B21","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.8005","article-title":"KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R\/R cHL) [abstract]","volume":"38","author":"Kuruvilla","year":"2020","journal-title":"J Clin Oncol."},{"article-title":"Nivolumab re-treatment in patients with relapsed\/refractory Hodgkin lymphoma","volume-title":"Proceedings from the International Symposium on Hodgkin Lymphoma","author":"Ansell","key":"2021081915275264200_B22"},{"key":"2021081915275264200_B23","doi-asserted-by":"crossref","DOI":"10.1002\/hon.176_2631","article-title":"Retreatment with nivolumab in patients with R\/R classical Hodgkin lymphoma after discontinuation of the therapy with immune checkpoint inhibitors [abstract]","volume":"37","author":"Fedorova","year":"2019","journal-title":"Hematol Oncol."},{"issue":"11","key":"2021081915275264200_B24","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.3324\/haematol.2019.242529","article-title":"Efficacy of anti-PD1 re-treatment in patients with Hodgkin lymphoma who relapsed after anti-PD1 discontinuation [letter]","volume":"105","author":"Manson","year":"2020","journal-title":"Haematologica."},{"key":"2021081915275264200_B25","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-127280","article-title":"Three-year follow-up of keynote-087: pembrolizumab monotherapy in relapsed\/refractory classic Hodgkin lymphoma [abstract]","volume":"134","author":"Zinzani","year":"2019","journal-title":"Blood."},{"issue":"21","key":"2021081915275264200_B26","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","article-title":"Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy","volume":"128","author":"Cheson","year":"2016","journal-title":"Blood."},{"issue":"12","key":"2021081915275264200_B27","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1182\/bloodadvances.2019001367","article-title":"KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure","volume":"4","author":"Armand","year":"2020","journal-title":"Blood Adv."},{"key":"2021081915275264200_B28","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V130.Suppl_1.738.738","article-title":"Phase II study of brentuximab vedotin plus ibrutinib for patients with relapsed\/refractory Hodgkin lymphoma [abstract]","volume":"130","author":"Chen","year":"2017","journal-title":"Blood."},{"issue":"2","key":"2021081915275264200_B29","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(17)30912-9","article-title":"Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin\u2019s lymphoma: an international, multicentre, single-arm, phase 1-2 trial","volume":"19","author":"O\u2019Connor","year":"2018","journal-title":"Lancet Oncol."},{"key":"2021081915275264200_B30","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hon.83_2629","article-title":"Extended follow-up of a phase I trial of ipilimumab, nivolumab and brentuximab vedotin in relapsed Hodgkin lymphoma: a trial of the ECOG-ACRIN research group (E4412) [abstract]","volume":"37","author":"Diefenbach","year":"2019","journal-title":"Hematol Oncol."},{"issue":"3","key":"2021081915275264200_B31","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/s41375-020-0939-1","article-title":"A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed\/refractory lymphoid malignancies","volume":"35","author":"Armand","year":"2021","journal-title":"Leukemia."},{"key":"2021081915275264200_B32","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-123163","article-title":"Preliminary results from a phase I trial of pembrolizumab plus vorinostat in patients with relapsed or refractory diffuse large B-cell lymphoma, follicular lymphoma, and Hodgkin lymphoma [abstract]","volume":"134","author":"Herrera","year":"2019","journal-title":"Blood."},{"issue":"17","key":"2021081915275264200_B33","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1200\/JCO.18.02151","article-title":"Addition of low-dose decitabine to anti-PD-1 antibody camrelizumab in relapsed\/refractory classical Hodgkin lymphoma","volume":"37","author":"Nie","year":"2019","journal-title":"J Clin Oncol."},{"issue":"3","key":"2021081915275264200_B34","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood.V97.3.616","article-title":"A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model","volume":"97","author":"Moskowitz","year":"2001","journal-title":"Blood."},{"issue":"10","key":"2021081915275264200_B35","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/annonc\/mdf221","article-title":"Time-intensified dexamethasone\/cisplatin\/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin\u2019s disease","volume":"13","author":"Josting","year":"2002","journal-title":"Ann Oncol."},{"issue":"1","key":"2021081915275264200_B36","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3324\/haematol.10661","article-title":"Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin\u2019s lymphoma","volume":"92","author":"Santoro","year":"2007","journal-title":"Haematologica."},{"issue":"12","key":"2021081915275264200_B37","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/annonc\/mdg496","article-title":"Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin\u2019s disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group","volume":"14","author":"Baetz","year":"2003","journal-title":"Ann Oncol."},{"issue":"6","key":"2021081915275264200_B38","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/annonc\/mdm090","article-title":"Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin\u2019s lymphoma: CALGB 59804","volume":"18","author":"Bartlett","year":"2007","journal-title":"Ann Oncol."},{"issue":"27","key":"2021081915275264200_B39","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1200\/JCO.2016.66.4466","article-title":"Bendamustine in combination with gemcitabine and vinorelbine is an effective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma: final results of a multicenter phase II study","volume":"34","author":"Santoro","year":"2016","journal-title":"J Clin Oncol."},{"issue":"23","key":"2021081915275264200_B40","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1182\/blood-2010-05-282756","article-title":"Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma","volume":"116","author":"Moskowitz","year":"2010","journal-title":"Blood."},{"issue":"7","key":"2021081915275264200_B41","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.3324\/haematol.2011.056051","article-title":"Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and\/or refractory Hodgkin\u2019s lymphoma responding to prior salvage therapy","volume":"97","author":"Devillier","year":"2012","journal-title":"Haematologica."},{"issue":"12","key":"2021081915275264200_B42","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1038\/bmt.2013.88","article-title":"Pre-transplant FDG-PET-based survival model in relaps3ed and refractory Hodgkin\u2019s lymphoma: outcome after high-dose chemotherapy and auto-SCT","volume":"48","author":"Akhtar","year":"2013","journal-title":"Bone Marrow Transplant."},{"issue":"6","key":"2021081915275264200_B43","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/bjh.12824","article-title":"F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma","volume":"165","author":"Gentzler","year":"2014","journal-title":"Br J Haematol."},{"issue":"3","key":"2021081915275264200_B44","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1470-2045(15)70013-6","article-title":"PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin\u2019s lymphoma: a non-randomised, open-label, single-centre, phase 2 study","volume":"16","author":"Moskowitz","year":"2015","journal-title":"Lancet Oncol."},{"issue":"12","key":"2021081915275264200_B45","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/j.bbmt.2015.07.018","article-title":"Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed\/refractory Hodgkin lymphoma","volume":"21","author":"Chen","year":"2015","journal-title":"Biol Blood Marrow Transplant."},{"issue":"3","key":"2021081915275264200_B46","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1093\/annonc\/mdx791","article-title":"Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma","volume":"29","author":"Herrera","year":"2018","journal-title":"Ann Oncol."},{"issue":"22","key":"2021081915275264200_B47","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.1834.1834","article-title":"Safety and activity of brentuximab vedotin (BV) plus ifosfamide, carboplatin, and etoposide (ICE) for relapsed\/refractory (Rel\/Ref) classical Hodgkin lymphoma (cHL): initial results of a phase I\/II trial [abstract]","volume":"128","author":"Cassaday","year":"2016","journal-title":"Blood."},{"key":"2021081915275264200_B48","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-123925","article-title":"Brentuximab vedotin in first refractory\/relapsed classical Hodgkin lymphoma patients treated by chemotherapy (ICE) before autologous transplantation. Final analysis of phase II study [abstract]","volume":"134","author":"Stamatoullas","year":"2019","journal-title":"Blood."},{"issue":"4","key":"2021081915275264200_B49","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1093\/annonc\/mdz009","article-title":"Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)","volume":"30","author":"Garcia-Sanz","year":"2019","journal-title":"Ann Oncol."},{"key":"2021081915275264200_B50","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-112235","article-title":"Combining brentuximab vedotin with DHAP as salvage treatment in relapsed\/refractory Hodgkin lymphoma: The phase II HOVON\/LLPC transplant BRaVE study [abstract]","volume":"132","author":"Hagenbeek","year":"2018","journal-title":"Blood."},{"issue":"9","key":"2021081915275264200_B51","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S1470-2045(18)30426-1","article-title":"Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin\u2019s lymphoma (AHOD1221): a Children\u2019s Oncology Group, multicentre single-arm, phase 1-2 trial","volume":"19","author":"Cole","year":"2018","journal-title":"Lancet Oncol."},{"issue":"1","key":"2021081915275264200_B52","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2017-11-815183","article-title":"Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma","volume":"132","author":"LaCasce","year":"2018","journal-title":"Blood."},{"issue":"11","key":"2021081915275264200_B53","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2017-10-811224","article-title":"Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"131","author":"Herrera","year":"2018","journal-title":"Blood."},{"key":"2021081915275264200_B54","article-title":"Brentuximab vedotin and nivolumab for relapsed or refractory classic hodgkin lymphoma: long-term follow-up results from the single-arm phase 1\/2 study [abstract]","volume":"134","author":"Moskowitz","year":"2019","journal-title":"Blood."},{"key":"2021081915275264200_B55","doi-asserted-by":"crossref","first-page":"8013","DOI":"10.1200\/JCO.2020.38.15_suppl.8013","article-title":"Nivolumab and brentuximab vedotin (BV)-based, response-adapted treatment in children, adolescents, and young adults (CAYA) with standard-risk relapsed\/refractory classical Hodgkin lymphoma (R\/R cHL): Primary analysis","volume":"38","author":"Cole","year":"2020","journal-title":"J Clin Oncol."},{"issue":"6","key":"2021081915275264200_B56","doi-asserted-by":"crossref","first-page":"755","DOI":"10.6004\/jnccn.2020.0026","article-title":"Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Hoppe","year":"2020","journal-title":"J Natl Compr Canc Netw."},{"key":"2021081915275264200_B57","doi-asserted-by":"crossref","first-page":"iv19","DOI":"10.1093\/annonc\/mdy080","article-title":"Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Eichenauer","year":"2018","journal-title":"Ann Oncol."},{"key":"2021081915275264200_B58","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-123162","article-title":"PET-Adapted Nivolumab or Nivolumab Plus ICE As First Salvage Therapy in Relapsed or Refractory Hodgkin Lymphoma [abstract]","volume":"134","author":"Herrera","year":"2019","journal-title":"Blood."},{"key":"2021081915275264200_B59","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-123879","article-title":"safety and toxicity profile of pembrolizumab (PEM) in combination with ICE chemotherapy followed by autologous stem cell transplantation for relapsed\/refractory classical Hodgkin lymphoma: no impairment in stem cell mobilization or engraftment [abstract]","volume":"134","author":"Bryan","year":"2019","journal-title":"Blood."},{"key":"2021081915275264200_B60","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-127575","article-title":"High complete response rate observed with second-line chemo-immunotherapy with pembrolizumab and GVD (gemcitabine, vinorelbine, and liposomal doxorubicin) in relapsed and refractory classical Hodgkin lymphoma [abstract]","volume":"134","author":"Moskowitz","year":"2019","journal-title":"Blood."},{"key":"2021081915275264200_B61","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2020-138434","article-title":"Phase II study of pembrolizumab plus GVD as second-line therapy for relapsed or refractory classical Hodgkin lymphoma","volume":"136","author":"Moskowitz","year":"2020","journal-title":"Blood."},{"issue":"1","key":"2021081915275264200_B62","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood.2019000215","article-title":"PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation","volume":"134","author":"Armand","year":"2019","journal-title":"Blood."},{"key":"2021081915275264200_B63","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood-2020-136384","article-title":"Consolidation with nivolumab and brentuximab vedotin after autologous hematopoietic cell transplantation in patients with high-risk Hodgkin lymphoma","volume":"136","author":"Herrera","year":"2020","journal-title":"Blood."},{"issue":"5","key":"2021081915275264200_B64","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jamaoncol.2018.6278","article-title":"Maintenance therapies for Hodgkin and non-Hodgkin lymphomas after autologous transplantation: a consensus project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT","volume":"5","author":"Kanate","year":"2019","journal-title":"JAMA Oncol."},{"issue":"16","key":"2021081915275264200_B65","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","author":"Andr\u00e9","year":"2017","journal-title":"J Clin Oncol."},{"issue":"10","key":"2021081915275264200_B66","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2018-01-827246","article-title":"CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET","volume":"132","author":"Straus","year":"2018","journal-title":"Blood."},{"issue":"5","key":"2021081915275264200_B67","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.2017.75.2543","article-title":"Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography\/computed tomography scan after two ABVD cyles: long-term results of the GITIL\/FIL HD 0607 trial","volume":"36","author":"Gallamini","year":"2018","journal-title":"J Clin Oncol."},{"issue":"8","key":"2021081915275264200_B68","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdu189","article-title":"ABVD (8 cycles) versus BEACOPP (4 escalated cycles \u2265 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial","volume":"25","author":"Mounier","year":"2014","journal-title":"Ann Oncol."},{"issue":"17","key":"2021081915275264200_B69","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/JCO.2015.64.5648","article-title":"Eight cycles of ABVD versus four cycles of BEACOPPescalated plus four cycles of BEACOPPbaseline in stage III to IV, international prognostic score \u2265 3, high-risk Hodgkin lymphoma: first results of the phase II EORTC 20012 intergroup trial","volume":"34","author":"Carde","year":"2016","journal-title":"J Clin Oncol."},{"issue":"12","key":"2021081915275264200_B70","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1080\/10428194.2020.1791846","article-title":"Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III\/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy","volume":"61","author":"Straus","year":"2020","journal-title":"Leuk Lymphoma."},{"key":"2021081915275264200_B71","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2020-137089","article-title":"Brentuximab vedotin with chemotherapy for patients with previously untreated, stage III\/IV classical Hodgkin lymphoma: 5-year update of the ECHELON-1 study","volume":"136","author":"Straus","year":"2020","journal-title":"Blood."},{"issue":"4","key":"2021081915275264200_B72","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med."},{"issue":"10","key":"2021081915275264200_B73","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood.2019003127","article-title":"Brentuximab vedotin with chemotherapy for stage III\/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study","volume":"135","author":"Straus","year":"2020","journal-title":"Blood."},{"issue":"7","key":"2021081915275264200_B74","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1182\/blood.2019001272","article-title":"Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma","volume":"134","author":"Abramson","year":"2019","journal-title":"Blood."},{"issue":"11","key":"2021081915275264200_B75","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1182\/bloodadvances.2020001871","article-title":"ABVD followed by BV consolidation in risk-stratified patients with limited-stage Hodgkin lymphoma","volume":"4","author":"Park","year":"2020","journal-title":"Blood Adv."},{"issue":"12","key":"2021081915275264200_B76","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/S1470-2045(17)30696-4","article-title":"Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin\u2019s lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group","volume":"18","author":"Eichenauer","year":"2017","journal-title":"Lancet Oncol."},{"issue":"23","key":"2021081915275264200_B77","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol."},{"issue":"23","key":"2021081915275264200_B78","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.19.00315","article-title":"Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the phase II CheckMate 205 study","volume":"37","author":"Ramchandren","year":"2019","journal-title":"J Clin Oncol."},{"key":"2021081915275264200_B79","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/hon.104_2629","article-title":"Nivolumab plus doxorubicin, vinblastine and dacarbazine for newly diagnosed advanced-stage classical Hodgkin lymphoma: checkmate 205 cohort d 2-year follow-up [abstract]","volume":"37","author":"Ansell","year":"2019","journal-title":"Hematol Oncol."},{"key":"2021081915275264200_B80","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-123906","article-title":"Brief pembrolizumab (PEM) monotherapy results in complete and near complete responses in the majority of untreated patients with classical Hodgkin lymphoma (cHL): a multicenter phase 2 PET-adapted study of sequential PEM and AVD [abstract]","volume":"134","author":"Allen","year":"2019","journal-title":"Blood."},{"issue":"6","key":"2021081915275264200_B81","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jamaoncol.2020.0750","article-title":"Efficacy of nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: the randomized phase 2 German Hodgkin Study Group NIVAHL trial","volume":"6","author":"Br\u00f6ckelmann","year":"2020","journal-title":"JAMA Oncol."},{"issue":"3","key":"2021081915275264200_B82","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1182\/blood-2011-09-378414","article-title":"A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era","volume":"119","author":"Evens","year":"2012","journal-title":"Blood."},{"issue":"1","key":"2021081915275264200_B83","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/bjh.12222","article-title":"The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496","volume":"161","author":"Evens","year":"2013","journal-title":"Br J Haematol."},{"issue":"26","key":"2021081915275264200_B84","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1182\/blood-2015-06-644336","article-title":"Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older","volume":"126","author":"Forero-Torres","year":"2015","journal-title":"Blood."},{"issue":"1","key":"2021081915275264200_B85","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/bjh.17073","article-title":"Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response-adapted design in the first-line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY)","volume":"193","author":"Gibb","year":"2021","journal-title":"Br J Haematol."},{"issue":"26","key":"2021081915275264200_B86","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1182\/blood-2017-06-787200","article-title":"Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged \u226560 years with HL","volume":"130","author":"Friedberg","year":"2017","journal-title":"Blood."},{"key":"2021081915275264200_B87","article-title":"Brentuximab vedotin and bendamustine as first-line treatment of Hodgkin lymphoma in the elderly (HALO Trial) [abstract]","volume":"38","author":"de Colella","year":"2020","journal-title":"J Clin Oncol."},{"key":"2021081915275264200_B88","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1182\/blood-2020-136583","article-title":"Frontline brentuximab vedotin as monotherapy or in combination for older hodgkin lymphoma patients [abstract]","volume":"136","author":"Yasenchak","year":"2020","journal-title":"Blood."},{"issue":"11","key":"2021081915275264200_B89","doi-asserted-by":"crossref","first-page":"e808","DOI":"10.1016\/S2352-3026(20)30275-1","article-title":"Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial","volume":"7","author":"Cheson","year":"2020","journal-title":"Lancet Haematol."},{"issue":"30","key":"2021081915275264200_B90","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1200\/JCO.2018.79.0139","article-title":"Multicenter phase II study of sequential brentuximab, vedotin, and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma","volume":"36","author":"Evens","year":"2018","journal-title":"J Clin Oncol."},{"issue":"15","key":"2021081915275264200_B91","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1182\/blood.2019000719","article-title":"Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III\/IV Hodgkin lymphoma","volume":"134","author":"Stephens","year":"2019","journal-title":"Blood."},{"issue":"2","key":"2021081915275264200_B92","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S1470-2045(18)30784-8","article-title":"PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study","volume":"20","author":"Casasnovas","year":"2019","journal-title":"Lancet Oncol."},{"issue":"7","key":"2021081915275264200_B93","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin\u2019s lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N Engl J Med."},{"issue":"18","key":"2021081915275264200_B94","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1182\/blood-2015-11-681064","article-title":"Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials","volume":"127","author":"B\u00f6ll","year":"2016","journal-title":"Blood."},{"issue":"5","key":"2021081915275264200_B95","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1158\/1078-0432.CCR-19-1768","article-title":"Inhibition of MDR1 overcomes resistance to brentuximab vedotin in Hodgkin lymphoma","volume":"26","author":"Chen","year":"2020","journal-title":"Clin Cancer Res."},{"issue":"24","key":"2021081915275264200_B96","doi-asserted-by":"crossref","first-page":"6292","DOI":"10.1182\/blood-2011-07-368167","article-title":"Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma","volume":"118","author":"B\u00f6ll","year":"2011","journal-title":"Blood."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/138\/7\/520\/1818095\/bloodbld2020007900c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/138\/7\/520\/1818095\/bloodbld2020007900c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T18:44:07Z","timestamp":1629398647000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/138\/7\/520\/475828\/How-I-incorporate-novel-agents-into-the-treatment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,22]]},"references-count":96,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,4,22]]},"published-print":{"date-parts":[[2021,8,19]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2020007900","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"type":"print","value":"0006-4971"},{"type":"electronic","value":"1528-0020"}],"subject":[],"published":{"date-parts":[[2021,4,22]]}}}